ArticleBMC cancer2025
A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.Translational andrology and urology · 2026Review
- MRI-derived features reveal recurrence heterogeneity in VI-RADS 2 non-muscle-invasive bladder cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-muscle invasive bladder cancer (NMIBC) has a high rate of postoperative recurrence and the efficacy of existing clinical prediction models is limited. This study aimed to combine multiparametric magnetic resonance imaging (mp-MRI) radiomic features with clinical characteristics to construct a machine learning model for accurately predicting the risk of recurrence within 2 years postoperatively in NMIBC patients. Retrospectively including 183 NMIBC patients (57 in the recurrence group, 126 in the non-recurrence group), radiomic features from mp-MRI imaging (T2W, ADC, and enhancement sequences) were extracted. Through LASSO selection, 4 key imaging features (MajorAxisLength, SZNN, S/V, Skewness) and 6 clinical features based on the EAU 2021 risk stratification were identified to constitute the clinical-imaging dataset. Through comparison with 10 machine learning models, Support Vector Machine (SVM) performed the best (training set AUC = 0.973, validation set AUC = 0.891), with external independent validation (108 cases) showing AUCs of 0.88 and 0.87, demonstrating good generalization ability. A bar chart integrating radiomics score (Rad-Score) with clinical features provides an intuitive prognostic tool. The study indicates that the clinical-imaging radiomics model based on SVM significantly enhances the efficacy of NMIBC recurrence prediction, addressing the shortcomings of traditional risk assessment and offering a reliable basis for personalized postoperative management. Study limitations include the retrospective design and the absence of molecular biomarkers, necessitating future multicenter prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.